Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Axonics Inc (NQ: AXNX )

70.98 UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Axonics Inc

< Previous 1 2 3 Next >
Axonics Reports Third Quarter 2024 Financial Results
From Axonics, Inc.
Via Business Wire
Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia
From Axonics, Inc.
Via Business Wire
Axonics Prevails in Patent Infringement Lawsuit with Medtronic
From Axonics, Inc.
Via Business Wire
Axonics Reports Second Quarter 2024 Financial Results
From Axonics, Inc.
Via Business Wire
Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia
From Axonics, Inc.
Via Business Wire
Axonics Reports First Quarter 2024 Financial Results
From Axonics, Inc.
Via Business Wire
Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Medical device maker Boston Scientific Co. defies Medtech slowdown and delivers a solid Q1 2024 earnings report, and raises 2024 outlook. 
Via MarketBeat
Axonics Stockholders Approve Merger Agreement with Boston Scientific
From Axonics, Inc.
Via Business Wire
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
From Axonics, Inc.
Via Business Wire
Axonics Responds to ITC Action by Medtronic
From Axonics, Inc.
Via Business Wire
Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results
From Axonics, Inc.
Via Business Wire
AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
AXNX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Axonics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Axonics Announces Definitive Agreement to be Acquired by Boston Scientific
From Axonics, Inc.
Via Business Wire
Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue
From Axonics, Inc.
Via Business Wire
Axonics to Present at the J.P. Morgan Healthcare Conference
From Axonics, Inc.
Via Business Wire
Revolutionizing Care: NeuroQure’s Groundbreaking Path to Treating Genetic Intellectual Disabilities
From NeuroQure
Via GlobeNewswire
Axonics to Participate in November Investor Conferences
From Axonics, Inc.
Via Business Wire
Axonics Reports Third Quarter 2023 Financial Results
From Axonics, Inc.
Via Business Wire
Axonics to Report Third Quarter 2023 Financial Results on October 30
From Axonics, Inc.
Via Business Wire
Axonics to Participate in September Investor Conferences
From Axonics, Inc.
Via Business Wire
Axonics Announces CFO Retirement and Appoints Successor
From Axonics, Inc.
Via Business Wire
Axonics Reports Second Quarter 2023 Financial Results
From Axonics, Inc.
Via Business Wire
Axonics to Report Second Quarter 2023 Financial Results on July 27
From Axonics, Inc.
Via Business Wire
Axonics Reports First Quarter 2023 Financial Results
From Axonics, Inc.
Via Business Wire
Axonics to Participate in Upcoming Investor Conferences
From Axonics, Inc.
Via Business Wire
Axonics Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral Neuromodulation
From Axonics, Inc.
Via Business Wire
Axonics to Report First Quarter 2023 Financial Results on May 1
From Axonics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.